Dynamic change of serum protein S100b and its clinical significance in patients with traumatic brain injury.
OBJECTIVE
To analyze the dynamic change of serum protein S100b in patients with traumatic brain injury and its clinical value in assessing brain damage.


METHODS
According to Glasgow coma scale (GCS), 102 cases of traumatic brain injury were divided into mild brain injury group (GCS > or = 13, n = 31, Group A), moderate brain injury group (8 < GCS < 13, n = 37, Group B) and severe brain injury group (GCS < or = 8, n = 34, Group C). Serial S100b concentrations were analyzed by enzyme-linked immunosorbent assay (ELISA) in blood samples taken on admission, 12 h, 24 h, 48 h, 72 h and 7 days after traumatic brain injury.


RESULTS
The severe brain injury group showed significantly higher concentration of serum S100b, with earlier increase and longer duration, than the mild and moderate brain injury groups. The patients with higher S100b exhibited lower GCS scores and poor clinical prognosis. The increase in S100b could emerge before clinical image evidence indicated so.


CONCLUSIONS
Serum S100b can be used as a sensitive index for assessment and prediction of traumatic brain injury severity and prognosis.
Chen
Da-qing
DQ
Department of Neurosurgery, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou, China. eillie@126.com
Zhu
Lie-lie
LL
D000293:Adolescent; D000328:Adult; D000368:Aged; D001930:Brain Injuries / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000097:blood*; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*
D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human